Press Releases

Keyword Search

Year

12/11/24

Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy

– Findings published in Brain Sciences showed missed doses and potential for injury when waking to t...

11/13/24

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

DUBLIN , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

11/12/24

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results

-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of ...

11/04/24

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12

DUBLIN , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

10/31/24

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

DUBLIN , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

10/24/24

Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances

Data demonstrated people with narcolepsy were significantly more likely to have sleep, mood and pain...

10/17/24

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive dayt...

09/25/24

Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent

– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study par...

09/03/24

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ ov...

08/28/24

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...

08/20/24

Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

DUBLIN , Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biophar...

08/08/24

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results

-- Generated $41.5 million in net revenue from sales of LUMRYZ™ -- -- More than 1,900 patients on LU...

08/01/24

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8

DUBLIN , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

07/31/24

Avadel Pharmaceuticals Announces First Patient Dosed in Phase 3 REVITALYZ™ Trial of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

DUBLIN , July 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

06/27/24

Avadel Pharmaceuticals to Join Russell 3000® Index

DUBLIN , June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceu...

05/30/24

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN , May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceut...

05/22/24

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefi...

05/21/24

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

DUBLIN, Ireland , May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...

05/08/24

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31 , greater tha...

05/01/24

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

DUBLIN, Ireland , May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biop...

04/01/24

Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

DUBLIN, Ireland , April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...

03/05/24

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland , March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bi...

03/04/24

Avadel Pharmaceuticals Issues Statement On Patent Litigation

DUBLIN, Ireland , March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), toda...

03/04/24

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sa...

02/26/24

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4

DUBLIN, Ireland , Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...

02/07/24

Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

DUBLIN, Ireland , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a bio...

01/08/24

Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights

-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the ...